{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:22:29Z","timestamp":1793125349872,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-90791-w","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T12:56:16Z","timestamp":1743771376000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Comparison of antimicrobial resistance in Pseudomonas aeruginosa from intensive care and non-intensive care units and its impact on treatment decisions"],"prefix":"10.1038","volume":"15","author":[{"given":"Racha","family":"Eid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"Dabar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia-Rossa","family":"Hanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gebrael","family":"Saliba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moussa","family":"Riachy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Choucair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rindala","family":"Saliba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"issue":"5","key":"90791_CR1","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1086\/338782","volume":"34","author":"DM Livermore","year":"2002","unstructured":"Livermore, D. M. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: Our worst nightmare? Clin. Infect. Dis. 34(5), 634\u2013640. https:\/\/doi.org\/10.1086\/338782 (2002).","journal-title":"Clin. Infect. Dis."},{"issue":"3","key":"90791_CR2","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"AP Magiorakos","year":"2012","unstructured":"Magiorakos, A. P. et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 18(3), 268\u2013281 (2012).","journal-title":"Clin. Microbiol. Infect."},{"key":"90791_CR3","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1093\/cid\/ciad428","volume":"1","author":"PD Tamma","year":"2023","unstructured":"Tamma, P. D. et al. Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections. Clin. Infect. Dis. 1, 428 (2023).","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"90791_CR4","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/2047-2994-3-32","volume":"3","author":"D Nathwani","year":"2014","unstructured":"Nathwani, D., Raman, G., Sulham, K., Gavaghan, M. & Menon, V. Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: A systematic review and meta-analysis. Antimicrob. Resist. Infect. Control 3(1), 32. https:\/\/doi.org\/10.1186\/2047-2994-3-32 (2014).","journal-title":"Antimicrob. Resist. Infect. Control"},{"issue":"2","key":"90791_CR5","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jhin.2019.06.005","volume":"103","author":"YP Tabak","year":"2019","unstructured":"Tabak, Y. P. et al. Incremental clinical and economic burden of suspected respiratory infections due to multi-drug-resistant Pseudomonas aeruginosa in the United States. J. Hosp. Infect. 103(2), 134\u2013141 (2019).","journal-title":"J. Hosp. Infect."},{"issue":"2","key":"90791_CR6","first-page":"399","volume":"12","author":"A Karruli","year":"2023","unstructured":"Karruli, A. et al. Evidence-based treatment of Pseudomonas aeruginosa infections: A critical reappraisal. Antibiot. Basel Switz. 12(2), 399 (2023).","journal-title":"Antibiot. Basel Switz."},{"issue":"6","key":"90791_CR7","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1111\/j.1469-0691.2007.01681.x","volume":"13","author":"N Mesaros","year":"2007","unstructured":"Mesaros, N. et al. Pseudomonas aeruginosa: Resistance and therapeutic options at the turn of the new millennium. Clin. Microbiol. Infect. 13(6), 560\u2013578 (2007).","journal-title":"Clin. Microbiol. Infect."},{"key":"90791_CR8","doi-asserted-by":"publisher","first-page":"212527","DOI":"10.7573\/dic.212527","volume":"7","author":"M Bassetti","year":"2018","unstructured":"Bassetti, M., Vena, A., Croxatto, A., Righi, E. & Guery, B. How to manage Pseudomonas aeruginosa infections. Drugs Context 7, 212527 (2018).","journal-title":"Drugs Context"},{"key":"90791_CR9","unstructured":"Comit\u00e9 de l\u2019Antibiograme de la Soci\u00e9t\u00e9 Fran\u00e7aise de Microbiologie. Soci\u00e9t\u00e9 Fran\u00e7aise de Microbiologie. https:\/\/www.sfm-microbiologie.org\/boutique\/_comite-de-lantibiogramme-de-la-sfm-ca-sfm-v1-0-juin-2024\/ (2024)."},{"key":"90791_CR10","unstructured":"Mastdiscs Combi Carba Plus. https:\/\/www.mast-group.com\/fr\/produits\/tests-de-r%25C3%25A9sistance-aux-antimicrobiens\/kit-de-d%25C3%25A9tection-des-m%25C3%25A9canismes-de-r%25C3%25A9sistances-aux-antibiotiques\/d73c\/ (2024)."},{"issue":"11","key":"90791_CR11","doi-asserted-by":"publisher","first-page":"4733","DOI":"10.1128\/AAC.49.11.4733-4738.2005","volume":"49","author":"C Juan","year":"2005","unstructured":"Juan, C. et al. Molecular mechanisms of \u03b2-lactam resistance mediated by AmpC hyperproduction in Pseudomonas aeruginosa clinical strains. Antimicrob. Agents Chemother. 49(11), 4733\u20134738 (2005).","journal-title":"Antimicrob. Agents Chemother."},{"key":"90791_CR12","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1093\/jac\/48.suppl_1.59","volume":"48","author":"DM Livermore","year":"2001","unstructured":"Livermore, D. M. & Brown, D. F. J. Detection of \u03b2-lactamase-mediated resistance. J. Antimicrob. Chemother. 48, 59\u201364. https:\/\/doi.org\/10.1093\/jac\/48.suppl_1.59 (2001).","journal-title":"J. Antimicrob. Chemother."},{"issue":"26","key":"90791_CR13","doi-asserted-by":"publisher","first-page":"15680","DOI":"10.1016\/S0021-9258(18)55452-1","volume":"265","author":"J Trias","year":"1990","unstructured":"Trias, J. & Nikaido, H. Protein D2 channel of the Pseudomonas aeruginosa outer membrane has a binding site for basic amino acids and peptides. J. Biol. Chem. 265(26), 15680\u201315684 (1990).","journal-title":"J. Biol. Chem."},{"issue":"5","key":"90791_CR14","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1111\/mmi.13346","volume":"100","author":"W Chen","year":"2016","unstructured":"Chen, W. et al. Novobiocin binding to NalD induces the expression of the MexAB-OprM pump in Pseudomonas aeruginosa. Mol. Microbiol. 100(5), 749\u2013758. https:\/\/doi.org\/10.1111\/mmi.13346 (2016).","journal-title":"Mol. Microbiol."},{"issue":"1","key":"90791_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1099\/jmm.0.000873","volume":"68","author":"A Rehman","year":"2019","unstructured":"Rehman, A., Patrick, W. M. & Lamont, I. L. Mechanisms of ciprofloxacin resistance in Pseudomonas aeruginosa: New approaches to an old problem. J. Med. Microbiol. 68(1), 1\u201310. https:\/\/doi.org\/10.1099\/jmm.0.000873 (2019).","journal-title":"J. Med. Microbiol."},{"issue":"1","key":"90791_CR16","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.biotechadv.2018.11.013","volume":"37","author":"Z Pang","year":"2019","unstructured":"Pang, Z., Raudonis, R., Glick, B. R., Lin, T. J. & Cheng, Z. Antibiotic resistance in Pseudomonas aeruginosa: Mechanisms and alternative therapeutic strategies. Biotechnol. Adv. 37(1), 177\u2013192 (2019).","journal-title":"Biotechnol. Adv."},{"key":"90791_CR17","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1099\/00221287-146-10-2543","volume":"10","author":"ELA Macfarlane","year":"2000","unstructured":"Macfarlane, E. L. A., Kwasnicka, A. & Hancock, R. E. W. Role of Pseudomonas aeruginosa PhoP-PhoQ in resistance to antimicrobial cationic peptides and aminoglycosides. Microbiology 10, 2543\u20132554. https:\/\/doi.org\/10.1099\/00221287-146-10-2543 (2000).","journal-title":"Microbiology"},{"key":"90791_CR18","unstructured":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Guidelines for the Treatment of Infections Caused by Multidrug-Resistant Gram-Negative Bacilli (Endorsed by European Society of Intensive Care Medicine)\u2014Clinical Microbiology and Infection. https:\/\/www.clinicalmicrobiologyandinfection.com\/article\/S1198-743X(21)00679-0\/fulltext (2024)."},{"issue":"3","key":"90791_CR19","doi-asserted-by":"publisher","first-page":"106270","DOI":"10.1016\/j.ijantimicag.2020.106270","volume":"57","author":"B Balandin","year":"2021","unstructured":"Balandin, B. et al. Multicenter study of ceftolozane\/tazobactam for treatment of Pseudomonas aeruginosa infections in critically ill patients. Int. J. Antimicrob. Agents 57(3), 106270 (2021).","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"2","key":"90791_CR20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1128\/aac.01117-20","volume":"65","author":"D Fournier","year":"2021","unstructured":"Fournier, D. et al. Mechanisms of resistance to ceftolozane\/tazobactam in Pseudomonas aeruginosa: Results of the GERPA multicenter study. Antimicrob. Agents Chemother. 65(2), 20. https:\/\/doi.org\/10.1128\/aac.01117-20 (2021).","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"90791_CR21","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13756-022-01187-8","volume":"11","author":"CM Gill","year":"2022","unstructured":"Gill, C. M., Nicolau, D. P., The ERACE-PA Global Study Group. Carbapenem-resistant Pseudomonas aeruginosa: An assessment of frequency of isolation from ICU versus non-ICU, phenotypic and genotypic profiles in a multinational population of hospitalized patients. Antimicrob. Resist. Infect. Control 11(1), 146. https:\/\/doi.org\/10.1186\/s13756-022-01187-8 (2022).","journal-title":"Antimicrob. Resist. Infect. Control"},{"issue":"4","key":"90791_CR22","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1097\/CCM.0b013e31823bc8d0","volume":"40","author":"KJ Eagye","year":"2012","unstructured":"Eagye, K. J., Banevicius, M. A. & Nicolau, D. P. Pseudomonas aeruginosa is not just in the intensive care unit any more: Implications for empirical therapy. Crit. Care Med. 40(4), 1329 (2012).","journal-title":"Crit. Care Med."},{"issue":"4","key":"90791_CR23","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3390\/tropicalmed8040205","volume":"8","author":"TA Hafiz","year":"2023","unstructured":"Hafiz, T. A. et al. Epidemiological, microbiological, and clinical characteristics of multi-resistant Pseudomonas aeruginosa isolates in King Fahad Medical City, Riyadh, Saudi Arabia. Trop. Med. Infect. Dis. 8(4), 205 (2023).","journal-title":"Trop. Med. Infect. Dis."},{"key":"90791_CR24","unstructured":"Multidrug-Resistant Pseudomonas aeruginosa. https:\/\/arpsp.cdc.gov\/profile\/antibiotic-resistance\/mdr-pseudomonas-aeruginosa (2024)."},{"issue":"2","key":"90791_CR25","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s40121-022-00591-2","volume":"11","author":"AJ Kunz Coyne","year":"2022","unstructured":"Kunz Coyne, A. J., El Ghali, A., Holger, D., Rebold, N. & Rybak, M. J. Therapeutic strategies for emerging multidrug-resistant Pseudomonas aeruginosa. Infect. Dis. Ther. 11(2), 661\u2013682. https:\/\/doi.org\/10.1007\/s40121-022-00591-2 (2022).","journal-title":"Infect. Dis. Ther."},{"issue":"11","key":"90791_CR26","first-page":"960","volume":"26","author":"F Barbier","year":"2010","unstructured":"Barbier, F. & Wolff, M. Multi-drug resistant Pseudomonas aeruginosa: Towards a therapeutic dead end? Med. Sci. 26(11), 960\u2013968 (2010).","journal-title":"Med. Sci."},{"issue":"1","key":"90791_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1099\/jmm.0.000873","volume":"68","author":"A Rehman","year":"2019","unstructured":"Rehman, A., Patrick, W. M. & Lamont, I. L. Mechanisms of ciprofloxacin resistance in Pseudomonas aeruginosa: New approaches to an old problem. J. Med. Microbiol. 68(1), 1\u201310 (2019).","journal-title":"J. Med. Microbiol."},{"key":"90791_CR28","unstructured":"Healthcare-Associated Infections in Intensive Care Units\u2014Annual Epidemiological Report for 2017. https:\/\/www.ecdc.europa.eu\/en\/publications-data\/healthcare-associated-infections-intensive-care-units-annual-epidemiological-1 (2019)."},{"issue":"1","key":"90791_CR29","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s40560-015-0120-5","volume":"3","author":"V Russotto","year":"2015","unstructured":"Russotto, V., Cortegiani, A., Raineri, S. M. & Giarratano, A. Bacterial contamination of inanimate surfaces and equipment in the intensive care unit. J. Intens. Care 3(1), 54. https:\/\/doi.org\/10.1186\/s40560-015-0120-5 (2015).","journal-title":"J. Intens. Care"},{"key":"90791_CR30","doi-asserted-by":"publisher","unstructured":"Increment Antimicrobial Resistance During the COVID-19 Pandemic: Results from the Invifar Network|Microbial Drug Resistance. https:\/\/doi.org\/10.1089\/mdr.2021.0231?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed (2024).","DOI":"10.1089\/mdr.2021.0231?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed"},{"key":"90791_CR31","unstructured":"COVID-19: U.S. Impact on Antimicrobial Resistance, Special Report 2022. https:\/\/stacks.cdc.gov\/view\/cdc\/117915 (National Center for Emerging and Zoonotic Infectious Diseases, 2022)."},{"issue":"3","key":"90791_CR32","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1097\/01.ccm.0000435665.07446.50","volume":"42","author":"S Blot","year":"2014","unstructured":"Blot, S. et al. Prevalence, risk factors, and mortality for ventilator-associated pneumonia in middle-aged, old, and very old critically ill patients. Crit. Care Med. 42(3), 601\u2013609 (2014).","journal-title":"Crit. Care Med."},{"key":"90791_CR33","unstructured":"Healthcare-Associated Infections Acquired in Intensive Care Units\u2014Annual Epidemiological Report for 2019. https:\/\/www.ecdc.europa.eu\/en\/publications-data\/healthcare-associated-infections-intensive-care-units-2019 (Accessed 24 September 2024) (2023)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90791-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90791-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90791-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T07:47:33Z","timestamp":1744271253000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-90791-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,2]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["90791"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-90791-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,2]]},"assertion":[{"value":"3 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This is a retrospective study that included strains collected from the laboratory, involving only de-identified data and previously collected specimens, and no direct involvement of human subjects or new interventions. The study protocol was approved and written informed consent was waived by the ethics committee of Hotel-Dieu de France Hospital affiliated to Saint Joseph University. This study was performed in accordance with the Declaration of Helsinki guidelines on the use of existing, anonymized data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"11288"}}